Agomab Therapeutics NV
AGMBNasdaq
$12.04
↓ -2.3%Jul 17 close · end-of-day
Price
1Y↓ -17.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
We are a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Our principal executive offices are located in Antwerpen, Belgium.
- CEO
- Tim Knotnerus
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 62
- Website
- www.agomab.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 23, 2026
Apr 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.